Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 31:17:3791-3798.
doi: 10.2147/IJGM.S475767. eCollection 2024.

Serum Lipoprotein(a) as Predictive Factor for Early Neurological Deterioration of Acute Ischemic Stroke After Thrombolysis

Affiliations

Serum Lipoprotein(a) as Predictive Factor for Early Neurological Deterioration of Acute Ischemic Stroke After Thrombolysis

Ruiming Wang et al. Int J Gen Med. .

Abstract

Objective: This study aimed to explore the relationship between serum lipoprotein(a) (LP(a)) levels and early neurological deterioration (END) in patients with acute ischemic stroke (AIS) after thrombolysis.

Methods: In total, 236 patients with AIS after thrombolysis were enrolled in this study. Serum LP(a) levels were measured on admission after thrombolysis. END was defined as an increase of at least two points in the NIHSS score within 48 hours after thrombolysis. Binary logistic regression analysis was used to assess the association between serum LP(a) levels and END.

Results: Overall, patients with END had higher LP(a) than those without END (high LP(a): 38.3% vs 22.2%, intermediate LP(a): 40.3% vs 41.8%, low LP(a): 21.3% vs 36.0%, p<0.005). In the multivariate analysis, high LP(a) (defined as LP(a) level 300 mg/L) was an independent risk factor for END post-thrombolysis (OR=3.154, 95% CI=1.067-9.322, p=0.038).

Conclusion: Our findings demonstrated that LP(a) was an independent risk factor for END post-thrombolysis and that LP(a) level 300 mg/L could be associated with END post-thrombolysis in this study population.

Keywords: Lipoprotein(a); acute ischemic stroke; early neurological deterioration; thrombolysis.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The patient flowchart.
Figure 2
Figure 2
Distributions of LP(a).
Figure 3
Figure 3
Distributions of LP(a) according to END.
Figure 4
Figure 4
Forest plots of binary logistic regression of serum level of LP(a) for END.

Similar articles

Cited by

References

    1. Ding Q, Liu S, Yao Y, Liu H, Cai T, Han L. Global, Regional, and National Burden of Ischemic Stroke, 1990-2019. Neurology. 2022;98(3):e279–e290. doi:10.1212/WNL.0000000000013115 - DOI - PubMed
    1. Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ. 2020;368(l6983). doi:10.1136/bmj.l6983 - DOI - PubMed
    1. Simonsen CZ, Schmitz ML, Madsen MH, et al. Early neurological deterioration after thrombolysis: clinical and imaging predictors. Int J Stroke. 2016;11(7):776–782. doi:10.1177/1747493016650454 - DOI - PubMed
    1. Werring D, Ozkan H, Doubal FN, et al. Early neurological deterioration in acute lacunar ischaemic stroke: systematic review of incidence, mechanisms, and prospects for treatment. Int J Stroke. 2024. doi:10.1177/17474930241273685 - DOI - PMC - PubMed
    1. Zhao W, Li S, Li C, et al. Effects of tirofiban on neurological deterioration in patients with acute ischemic stroke: a randomized clinical trial. JAMA Neurol. 2024;81(6):594. doi:10.1001/jamaneurol.2024.0868 - DOI - PMC - PubMed

LinkOut - more resources